1. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa
- Author
-
Chiara Moltrasio, Dalma Malvaso, Simone Garcovich, Angelo V. Marzano, and Giovanni Genovese
- Subjects
medicine.medical_specialty ,Severe disease ,Dermatology ,Disease ,Systemic inflammation ,Chronic inflammatory disease ,Hereditary autoinflammatory diseases ,Pyogenic arthritis, pyoderma gangrenosum, and acne ,Hidradenitis suppurativa ,Pathogenesis ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,030203 arthritis & rheumatology ,Inflammation ,business.industry ,Syndrome ,medicine.disease ,Hidradenitis ,Hidradenitis Suppurativa ,Follicular inflammation ,medicine.symptom ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,business - Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory disease usually involving the major skin folds characterized by a multifactorial pathogenesis and a wide spectrum of clinical manifestations. It can also rarely present in association with other diseases as complex clinical syndromes, causing additional diagnostic and therapeutic challenges. Different etiopathologic factors contribute to follicular inflammation and suppurative lesions of syndromic HS, including follicular hyperkeratinization and plugging, as well as activation of autoinflammatory pathways. Patients with syndromic HS frequently have a severe disease course, presenting with atypical skin involvement, signs of systemic inflammation, and resistance to conventional treatments. Systematic classification of syndromic HS is based on clinical, pathogenetic, and genetic factors, but it is constantly evolving due to increased disease awareness. Treatment of syndromic HS is difficult and should be personalized on a case-by-case basis. Investigating syndromic HS can lead to useful insights on genetics and pathogenesis, translating into new clinical approaches for sporadic hidradenitis. We review the classification, clinical presentation, disease associations, and therapeutic management of syndromic HS, focusing mainly on its autoinflammatory syndromes PASH, PAPASH, PsAPASH, and PASS.
- Published
- 2021